Some people change the way cancer is understood.
Professor Maura L. Gillison was one of those people.
Her work helped transform the understanding of HPV-related head and neck cancers, particularly cancers of the oropharynx — the part of the throat that includes the tonsils and the base of the tongue.
For many years, throat cancer was most commonly associated with smoking and alcohol. Those remain important risk factors. But the rise of HPV-related oropharyngeal cancer changed the conversation. It showed that a significant number of people being diagnosed did not fit the old stereotype of a throat cancer patient.
Professor Gillison’s research helped make that clear.
Her work contributed to the evidence that human papillomavirus, especially HPV16, is strongly linked to oropharyngeal cancer. It also helped establish that HPV-positive oropharyngeal cancer behaves differently from HPV-negative disease, including differences in prognosis and response to treatment.
That matters.
It matters to patients, because understanding the type of cancer they have can influence how clinicians think about treatment and outcomes.
It matters to researchers, because HPV-related throat cancer is not simply “the same cancer in a different patient”. It is biologically distinct and needs to be studied properly.
And it matters to public health, because HPV vaccination is not only about cervical cancer. It is also part of preventing future HPV-related cancers, including some mouth and throat cancers.
At the Throat Cancer Foundation, this is central to our work.
We believe prevention must be taken seriously. We believe HPV vaccination should be understood as cancer prevention. We believe boys and girls both deserve protection. And we believe the public should know that HPV-related throat cancer is real, common enough to matter, and too often still poorly understood.
The connection between HPV and throat cancer is not opinion. It is built on decades of serious scientific work by researchers, clinicians and scientists, including Professor Gillison, whose contribution helped change the field.
That work has given patients better explanations. It has given clinicians better evidence. And it has given organisations like ours a stronger foundation from which to speak clearly about prevention, vaccination and earlier diagnosis.
Professor Gillison’s legacy is not only in the scientific papers, the awards or the medical conferences.
It is also in every conversation that now starts with a better understanding of why HPV matters.
It is in every parent who realises the HPV vaccine protects against more than one cancer.
It is in every patient who hears that their diagnosis has a cause, a biology and a body of research behind it.
And it is in the public health message we will continue to repeat:
Prevention where we can. Earlier diagnosis where we can’t.
Professor Maura Gillison’s work helped make that message stronger.
For that, the throat cancer community owes her a great deal.
For further information;-
